TNFRSF10A and ovarian serous adenocarcinoma: Many research studies have demonstrated that CTBP2 and CTBP1 (C-terminal binding protein 1) have an extremely important role in suppressing the expression and activity of DR4/5 (death-receptors 4/5), and may maintain the possibility of CTBP as a high-grade serous ovarian cancer (HGSOC) treatment strategy [31].